Ask AI
ProCE Banner Activity

Frontline Immune Checkpoint Inhibitor Therapy in Advanced Head and Neck Cancer

Slideset Download
Downloadable slides review the optimal use of immune checkpoint inhibitors in the frontline setting in patients with advanced metastatic head and neck cancer.

Released: November 10, 2020

Expiration: November 09, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bayer Healthcare Pharma

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Chief Translational Officer
Associate Director, Translational Research
Chief, Head and Neck/Sarcoma Oncology
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Barbara Burtness, MD, has disclosed that she has received consulting fees from Aduro, ALX Oncology, Celgene, Chemotherapy Advisory, Cue Biopharma, Debio Pharm, GlaxoSmithKline, Io Biotech, Kura, Macrogenics, Maverick, Merck, Nanobiotix, and Rakuten.